Share on StockTwits

bluebird bio (NASDAQ:BLUE) CEO Nick Leschly sold 17,075 shares of the company’s stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $40.06, for a total value of $684,024.50. Following the sale, the chief executive officer now directly owns 355,584 shares of the company’s stock, valued at approximately $14,244,695. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of bluebird bio (NASDAQ:BLUE) traded down 0.59% on Tuesday, hitting $38.57. 321,774 shares of the company’s stock traded hands. bluebird bio has a 1-year low of $17.03 and a 1-year high of $41.75. The stock’s 50-day moving average is $25.30 and its 200-day moving average is $23.13. The company’s market cap is $945.4 million.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.12. The company had revenue of $6.30 million for the quarter, compared to the consensus estimate of $6.23 million. On average, analysts predict that bluebird bio will post $-1.78 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on BLUE shares. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of bluebird bio in a research note on Wednesday, June 18th. They now have a $53.00 price target on the stock, up previously from $44.00. Separately, analysts at Wedbush raised their price target on shares of bluebird bio to $51.00 in a research note on Monday, June 16th. Finally, analysts at Piper Jaffray initiated coverage on shares of bluebird bio in a research note on Friday, June 13th. They set an “overweight” rating on the stock. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. bluebird bio has a consensus rating of “Buy” and an average price target of $42.48.

bluebird bio, Inc is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.